An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Neonatal diabetes mellitus (NDM) is rare, with a prevalence of ∼1 in 500,000 infants worldwide. NDM may be caused by several different genetic abnormalities, and might either be transient (TNDM) or permanent. Until recently, clinical management of most permanent types of NDM required lifelong subcutaneous insulin treatment. However, due to activating mutations in the genes that encode the adenosine triphosphate-sensitive K+ channel, some permanent types of NDM have been found to be amenable to oral sulfonylurea therapy. TNDM can last for a median of 12 weeks and completely resolve by 18 months. Although TNDM is typically treated with subcutaneous insulin, this mode of therapy might be difficult for some caregivers. Case summary: A small for gestational age male infant born at term developed NDM on day of life (DOL) 3. No other factors, such as sepsis, infection, or dextrose-containing intravenous fluids, that could have accounted for the hyperglycemia were present. In addition, there was no family history of DM or hyper-glycemic disorders. The patient was initially treated with subcutaneous regular insulin (0.25 U at a concentration of 10 U/L) q4h PRN for blood glucose concentrations >200 mg/dL. However, due to persistent blood glucose concentration fluctuations, a continuous insulin infusion (0.05 U/kg/h) was started on DOL 7. Because subcutaneous insulin injections could not be administered by the parents outside of the hospital, oral sulfonylurea therapy was attempted. A glyburide oral suspension, prepared by dissolving half of a 1.25-mg tablet in 1 mL of preservative-free, sterile water, was started at 0.2 mg/kg/d in 2 divided doses. The suspension was prepared immediately prior to each dose and was administered via syringe during feedings. On DOL 21, the patient's NDM was managed solely with an oral sulfonylurea, target blood glucose concentrations of 150 to 250 mg/dL were achieved with glyburide 0.7 mg/kg/d in 2 divided doses, and insulin administration was no longer required. On DOL 25, the glyburide dosage was decreased to 0.5 mg/kg/d in 2 divided doses. On DOL 27, the patient was discharged on the same dosage. The patient's NDM subsequently resolved by DOL 49. Conclusion: An oral sulfonylurea was a useful treatment option in the management of TNDM in this patient.

Original languageEnglish (US)
Pages (from-to)816-820
Number of pages5
JournalClinical Therapeutics
Volume31
Issue number4
DOIs
StatePublished - Apr 2009

Fingerprint

Diabetes Mellitus
Insulin
Glyburide
Blood Glucose
Suspensions
Therapeutics
Small for Gestational Age Infant
Syringes
Subcutaneous Injections
Hyperglycemia
Caregivers
Tablets
Sepsis
Adenosine Triphosphate
Parents
Glucose
Mutation
Water
Infection
Genes

Keywords

  • glyburide
  • neonatal diabetes mellitus
  • sulfonylurea

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus. / Loomba-Albrecht, Lindsey A; Glaser, Nicole; Styne, Dennis M; Bremer, Andrew A.

In: Clinical Therapeutics, Vol. 31, No. 4, 04.2009, p. 816-820.

Research output: Contribution to journalArticle

@article{05ad85cedf904755862daf3730b9e0ed,
title = "An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus",
abstract = "Background: Neonatal diabetes mellitus (NDM) is rare, with a prevalence of ∼1 in 500,000 infants worldwide. NDM may be caused by several different genetic abnormalities, and might either be transient (TNDM) or permanent. Until recently, clinical management of most permanent types of NDM required lifelong subcutaneous insulin treatment. However, due to activating mutations in the genes that encode the adenosine triphosphate-sensitive K+ channel, some permanent types of NDM have been found to be amenable to oral sulfonylurea therapy. TNDM can last for a median of 12 weeks and completely resolve by 18 months. Although TNDM is typically treated with subcutaneous insulin, this mode of therapy might be difficult for some caregivers. Case summary: A small for gestational age male infant born at term developed NDM on day of life (DOL) 3. No other factors, such as sepsis, infection, or dextrose-containing intravenous fluids, that could have accounted for the hyperglycemia were present. In addition, there was no family history of DM or hyper-glycemic disorders. The patient was initially treated with subcutaneous regular insulin (0.25 U at a concentration of 10 U/L) q4h PRN for blood glucose concentrations >200 mg/dL. However, due to persistent blood glucose concentration fluctuations, a continuous insulin infusion (0.05 U/kg/h) was started on DOL 7. Because subcutaneous insulin injections could not be administered by the parents outside of the hospital, oral sulfonylurea therapy was attempted. A glyburide oral suspension, prepared by dissolving half of a 1.25-mg tablet in 1 mL of preservative-free, sterile water, was started at 0.2 mg/kg/d in 2 divided doses. The suspension was prepared immediately prior to each dose and was administered via syringe during feedings. On DOL 21, the patient's NDM was managed solely with an oral sulfonylurea, target blood glucose concentrations of 150 to 250 mg/dL were achieved with glyburide 0.7 mg/kg/d in 2 divided doses, and insulin administration was no longer required. On DOL 25, the glyburide dosage was decreased to 0.5 mg/kg/d in 2 divided doses. On DOL 27, the patient was discharged on the same dosage. The patient's NDM subsequently resolved by DOL 49. Conclusion: An oral sulfonylurea was a useful treatment option in the management of TNDM in this patient.",
keywords = "glyburide, neonatal diabetes mellitus, sulfonylurea",
author = "Loomba-Albrecht, {Lindsey A} and Nicole Glaser and Styne, {Dennis M} and Bremer, {Andrew A.}",
year = "2009",
month = "4",
doi = "10.1016/j.clinthera.2009.04.003",
language = "English (US)",
volume = "31",
pages = "816--820",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "4",

}

TY - JOUR

T1 - An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus

AU - Loomba-Albrecht, Lindsey A

AU - Glaser, Nicole

AU - Styne, Dennis M

AU - Bremer, Andrew A.

PY - 2009/4

Y1 - 2009/4

N2 - Background: Neonatal diabetes mellitus (NDM) is rare, with a prevalence of ∼1 in 500,000 infants worldwide. NDM may be caused by several different genetic abnormalities, and might either be transient (TNDM) or permanent. Until recently, clinical management of most permanent types of NDM required lifelong subcutaneous insulin treatment. However, due to activating mutations in the genes that encode the adenosine triphosphate-sensitive K+ channel, some permanent types of NDM have been found to be amenable to oral sulfonylurea therapy. TNDM can last for a median of 12 weeks and completely resolve by 18 months. Although TNDM is typically treated with subcutaneous insulin, this mode of therapy might be difficult for some caregivers. Case summary: A small for gestational age male infant born at term developed NDM on day of life (DOL) 3. No other factors, such as sepsis, infection, or dextrose-containing intravenous fluids, that could have accounted for the hyperglycemia were present. In addition, there was no family history of DM or hyper-glycemic disorders. The patient was initially treated with subcutaneous regular insulin (0.25 U at a concentration of 10 U/L) q4h PRN for blood glucose concentrations >200 mg/dL. However, due to persistent blood glucose concentration fluctuations, a continuous insulin infusion (0.05 U/kg/h) was started on DOL 7. Because subcutaneous insulin injections could not be administered by the parents outside of the hospital, oral sulfonylurea therapy was attempted. A glyburide oral suspension, prepared by dissolving half of a 1.25-mg tablet in 1 mL of preservative-free, sterile water, was started at 0.2 mg/kg/d in 2 divided doses. The suspension was prepared immediately prior to each dose and was administered via syringe during feedings. On DOL 21, the patient's NDM was managed solely with an oral sulfonylurea, target blood glucose concentrations of 150 to 250 mg/dL were achieved with glyburide 0.7 mg/kg/d in 2 divided doses, and insulin administration was no longer required. On DOL 25, the glyburide dosage was decreased to 0.5 mg/kg/d in 2 divided doses. On DOL 27, the patient was discharged on the same dosage. The patient's NDM subsequently resolved by DOL 49. Conclusion: An oral sulfonylurea was a useful treatment option in the management of TNDM in this patient.

AB - Background: Neonatal diabetes mellitus (NDM) is rare, with a prevalence of ∼1 in 500,000 infants worldwide. NDM may be caused by several different genetic abnormalities, and might either be transient (TNDM) or permanent. Until recently, clinical management of most permanent types of NDM required lifelong subcutaneous insulin treatment. However, due to activating mutations in the genes that encode the adenosine triphosphate-sensitive K+ channel, some permanent types of NDM have been found to be amenable to oral sulfonylurea therapy. TNDM can last for a median of 12 weeks and completely resolve by 18 months. Although TNDM is typically treated with subcutaneous insulin, this mode of therapy might be difficult for some caregivers. Case summary: A small for gestational age male infant born at term developed NDM on day of life (DOL) 3. No other factors, such as sepsis, infection, or dextrose-containing intravenous fluids, that could have accounted for the hyperglycemia were present. In addition, there was no family history of DM or hyper-glycemic disorders. The patient was initially treated with subcutaneous regular insulin (0.25 U at a concentration of 10 U/L) q4h PRN for blood glucose concentrations >200 mg/dL. However, due to persistent blood glucose concentration fluctuations, a continuous insulin infusion (0.05 U/kg/h) was started on DOL 7. Because subcutaneous insulin injections could not be administered by the parents outside of the hospital, oral sulfonylurea therapy was attempted. A glyburide oral suspension, prepared by dissolving half of a 1.25-mg tablet in 1 mL of preservative-free, sterile water, was started at 0.2 mg/kg/d in 2 divided doses. The suspension was prepared immediately prior to each dose and was administered via syringe during feedings. On DOL 21, the patient's NDM was managed solely with an oral sulfonylurea, target blood glucose concentrations of 150 to 250 mg/dL were achieved with glyburide 0.7 mg/kg/d in 2 divided doses, and insulin administration was no longer required. On DOL 25, the glyburide dosage was decreased to 0.5 mg/kg/d in 2 divided doses. On DOL 27, the patient was discharged on the same dosage. The patient's NDM subsequently resolved by DOL 49. Conclusion: An oral sulfonylurea was a useful treatment option in the management of TNDM in this patient.

KW - glyburide

KW - neonatal diabetes mellitus

KW - sulfonylurea

UR - http://www.scopus.com/inward/record.url?scp=65549149008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549149008&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2009.04.003

DO - 10.1016/j.clinthera.2009.04.003

M3 - Article

C2 - 19446154

AN - SCOPUS:65549149008

VL - 31

SP - 816

EP - 820

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 4

ER -